ArticleBriefings in bioinformatics2025
Protrec2: tissue-specific network-based missing protein recovery method.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite technological advances, missing proteins remain a challenge in proteomics, obscuring proteins that are biologically or clinically important. We present Protrec2, a probabilistic framework that integrates tissue-specific protein complex annotations with Bayesian inference to recover unreported but biologically present proteins. We benchmarked Protrec2 on HeLa and A549-derived proteomes under "upper-bound" and "lower-bound" scenarios, reflecting distinct but complementary real-world use cases. In upper-bound evaluations, Protrec2 consistently outperformed state-of-the-art methods such as PROTein RECovery, Functional Class Scoring, Hypergeometric Enrichment, and Gene Set Enrichment Analysis, achieving the highest recovery rates: up to 98.4% in A549 and 96.5% in HeLa and validating 650 and 453 proteins, respectively. In lower-bound evaluations, Protrec2 maintained superior precision, validating over 90% of its predicted proteins in the A549 dataset and 74.6% in HeLa, while other methods exhibited significant performance drops. We applied Protrec2 to six matched lung tumor-normal pairs and validated predictions against CPTAC. Over 85% of predicted proteins were supported, with cancer-specific proteins mostly upregulated and normal-exclusive ones downregulated. Frequently recovered proteins (e.g. P4HA3, SNX1, HIP1R, NOS2) are known to play key roles in lung cancer, highlighting the biological and clinical relevance of Protrec2. These findings establish Protrec2 as a robust, biologically grounded tool for missing protein recovery, with broad applicability in discovery proteomics and translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.